Relapsed or refractory aggressive B-cell lymphoma has an extremely poor prognosis and
efforts to develop novel therapies for these patients have failed for almost four decades until …

Summary CD19 CAR‐T have emerged as a new standard treatment for relapsed/refractory
(r/r) large B‐cell lymphoma (LBCL). CAR‐T real‐world (RW) outcomes published to date …

Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the
multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28 …

Background: The standard of care (SOC) treatment (Tx) in the curative setting for patients
(pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after 1st-line (1L) …

Introduction CD19 directed CAR T cells have potent activity in relapsed/refractory (R/R)
aggressive B-cell lymphomas (B-NHL) leading to the FDA approval of axicabtagene …

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are autologous anti-CD19
chimeric antigen receptor T (CAR T) cell therapies for the treatment of patients with …

Introduction Tisagenlecleucel is a CD19-directed genetically modified autologous T-cell
immunotherapy approved for the treatment of adult patients with relapsed or refractory large …

Chimeric antigen receptor (CAR) T-cell therapies that specifically target the CD19 antigen
have emerged as a highly effective treatment option in patients with refractory B-cell …

Chimeric antigen receptor T cell (CAR-T) therapy has emerged as highly effective in
relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but only about 40 …

PURPOSE Two anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies are approved
for diffuse large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel; …